<QuerySet [<Slide: Fundamentals of Solid Formulation | Weekly Webinar Series>, <Slide: Building an AI-powered Drug R&D Engine>, <Slide: AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment>, <Slide: How Quantum Physics and AI is Disrupting Drug Discovery & Development>, <Slide: XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement>]>

XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets
Learn More

Fundamentals of Solid Formulation | Weekly Webinar Series

April 7, 14, 21, 28, May 5, 12, 19 | 11:00 AM – Noon EDT
Learn More

Building an AI-powered Drug R&D Engine

to empower pharmaceutical research with increased efficiency and success rate.
Learn More

AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment

Led by SoftBank Vision Fund, PICC Capital, and Morningside
Learn More

How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping Pfizer scientists predict and optimize the crystalline forms of drug candidates.
Learn More

XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets
Learn More

Fundamentals of Solid Formulation | Weekly Webinar Series

April 7, 14, 21, 28, May 5, 12, 19 | 11:00 AM – Noon EDT
Learn More

Drug Solid-State R&D

For solid-state R&D of small molecule drugs, our solution integrates several state-of-the-art technologies for crystal structure prediction, crystal structure determination, virtual screening of salts and cocrystals, as well as an advanced solid-state R&D experimental platform. We are dedicated to creating the next-generation platform for solid-state R&D for small molecules by combining experimental screening and characterization with theoretical calculations and analyses, and providing novel solutions for the solid-state R&D. At XtalPi, we help our clients improve the quality and efficiency of solid-state R&D and reduce related risks and costs.

Contact us
banner
June 16, 2020-July 29, 2020
online
...
Research Collaboration between XtalPi Inc and Acerand Therapeutics to develop potential novel anti-cancer therapies using High-precision Physics-based model and Machine Learning

The partnership will leverage XtalPi’s highly accurate physics-based models and machine learning models to develop potential novel chemical entities for a cancer target.

...
XtalPi and Sedec Therapeutics announces the collaboration of novel therapeutics development against autoimmune diseases

XtalPi and Sedec have recently reached an agreement to develop novel small-molecule therapeutics targeting STAT3 palmitoylation pathway for auto immune disorder diseases treatment.

...
XtalPi Invests in Novel Target Discovery Biotech PhoreMost in Oversubscribed Series B Financing

XtalPi’s investment will allow the two companies to deepen their partnership in AI drug discovery against challenging novel targets